SINO BIOPHARM (01177) announced that its self-developed innovative drug, TQF3250 capsules—an "oral biased GLP-1 receptor agonist"—has received clinical trial approval from China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) for weight management. TQF3250 is an oral small-molecule biased GLP-1 receptor agonist. Compared to traditional GLP-1 drugs, TQF3250 selectively activates the cAMP-biased GLP-1 receptor signaling pathway, enhancing insulin secretion while reducing β-arrestin recruitment and receptor internalization, thereby prolonging its therapeutic effect. With its unique mechanism, TQF3250 is expected to deliver superior blood sugar and weight control with significantly fewer gastrointestinal side effects. Unlike mainstream injectable GLP-1 drugs, its oral administration offers greater convenience and long-term treatment adherence for patients.

Overweight and obesity have become one of the most pressing public health challenges of the 21st century. According to the World Obesity Atlas 2025 report, the global prevalence of overweight and obese adults is projected to rise from 36% in 2000 to 50% by 2030, affecting nearly 3 billion people. In China, this trend is particularly pronounced, with 41% of adults already classified as having a high BMI (≥25kg/m²) in 2025, and 9% meeting obesity criteria (BMI≥30kg/m²). By 2030, China is expected to have 515 million adults with high BMI.

Beyond weight management, TQF3250 has also received NMPA approval for clinical trials targeting type 2 diabetes. Metabolic diseases remain a core therapeutic focus for the group, which aims to provide patients with a diversified pipeline of treatment options.